Physician profile
David M Lyons
NPI 1639533243
$3,187.76
in general payments reported to CMS, 2019-2025
31 companies · $695 in 2025
The $695 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $891 · 2022: $505 · 2023: $584 · 2024: $513 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $634.75 | 2021-2025 | Breztri, Farxiga |
| Abbvie INC. | $401.05 | 2021-2025 | |
| Glaxosmithkline, LLC. | $395.20 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $220.65 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $200.11 | 2021-2025 | |
| Abbott Laboratories | $172.91 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $108.69 | 2023-2024 | Gardasil 9, Rotateq, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company Ltd. | $92.46 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $89.24 | 2021 | |
| Idorsia Pharmaceuticals US INC | $79.61 | 2023-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $76.96 | 2021-2022 | |
| Amgen INC. | $73.10 | 2025 | Repatha, Otezla |
| Exact Sciences Corporation | $67.49 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $62.66 | 2021-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $42.95 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.45 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $40.79 | 2023-2025 | Gvoke Hypopen |
| Eisai INC. | $40.25 | 2021 | |
| Novartis Pharmaceuticals Corporation | $37.14 | 2021 | |
| Collegium Pharmaceutical, INC. | $37.06 | 2025 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $35.94 | 2021-2024 | Zoryve |
| Medtronic, INC. | $35.48 | 2022 | |
| Supernus Pharmaceuticals, INC. | $33.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.73 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $25.45 | 2021 | |
| Sage Therapeutics, LLC | $18.39 | 2024 | |
| Impel Pharmaceuticals INC. | $18.19 | 2023 | Trudhesa |
| Scilex Pharmaceuticals INC. | $17.93 | 2024 | |
| Esperion Therapeutics, INC. | $14.45 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.